Page 17 - Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction – Full text

Guideline: Neurogenic bladder

71. Martínez-Salamanca JI, Carballido J, Eardley I, et al. Phosphodiesterase type 5 inhibitors in the manage- 96. Lapides J, Diokno AC, Silber SJ, et al. Clean, intermittent self-catheterization in the treatment of urinary
ment of non-neurogenic male lower urinary tract symptoms: Critical analysis of current evidence. Eur Urol tract disease. J Urol 1972;107:458-61. https://doi.org/10.1016/S0022-5347(17)61055-3
2011;60:527-35. https://doi.org/10.1016/j.eururo.2011.05.054 97. Binard JE, Persky L, Lockhart JL, et al. Intermittent catheterization the right way! (Volume vs. time-
72. Zelaya JE, Murchison C, Cameron M. Associations between bladder dysfunction and falls in people with directed). J Spinal Cord Med 1996;19:194-6. https://doi.org/10.1080/10790268.1996.11719432
relapsing-remitting multiple sclerosis. Int J MS Care 2017;19:184-90. https://doi.org/10.7224/1537- 98. Cornejo-Davila V, Duran-Ortiz S, Pacheco-Gahbler C. Incidence of urethral stricture in patients with
2073.2016-049 spinal cord injury treated with clean intermittent self-catheterization. Urology 2017;99:260-4.
73. Flack C, Powell CR. The worldwide economic impact of neurogenic bladder. Curr Bladder Dysfunct Rep https://doi.org/10.1016/j.urology.2016.08.024
2015;10:350-4. https://doi.org/10.1007/s11884-015-0323-6 99. Christison K, Walter M, Wyndaele JJM, et al. Intermittent catheterization: The devil is in the details. J
74. Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with Neurotrauma 2018 Feb 1. [Epub ahead of print]. https://doi.org/10.1089/neu.2017.5413
spinal cord injury. Phys Ther 2002;82:601-12. 100. Talbot HS, Mahoney EM, Jaffee SR. The effects of prolonged urethral catheterization. I. Persistence
75. Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 2002;113 of normal renal structure and function. J Urol 1959;81:138-45. https://doi.org/10.1016/S0022-
Suppl 1A:67S-79S. https://doi.org/10.1016/S0002-9343(02)01061-6 5347(17)65979-2
76. Biering-Sorensen F, Nielans HM, Dorflinger T, et al. Urological situation five years after spinal cord injury. 101. Dewire DM, Owens RS, Anderson GA, et al. A comparison of the urological complications associated
Scand J Urol Nephrol 1999;33:157-61. https://doi.org/10.1080/003655999750015925 with long-term management of quadriplegics with and without chronic indwelling urinary catheters.
77. Togan T, Azap OK, Durukan E, et al. The prevalence, etiologic agents and risk factors for uri-The prevalence, etiologic agents and risk factors for uri- J Urol 1992;147:1069-71; discussion 71-2. https://doi.org/10.1016/S0022-5347(17)37472-4
nary tract infection among spinal cord injury patients. Jundishapur J Microbiol 2014;7:e8905. 102. MacDiarmid SA, Arnold EP, Palmer NB, et al. Management of spinal cord injured patients by indwelling supra-Management of spinal cord injured patients by indwelling supra-
https://doi.org/10.5812/jjm.8905 pubic catheterization. J Urol 1995;154:492-4. https://doi.org/10.1016/S0022-5347(01)67083-6
78. Yoon SB, Lee BS, Lee KD, et al. Comparison of bacterial strains and antibiotic susceptibilities in urinary 103. Sugimura T, Arnold E, English S, et al. Chronic suprapubic catheterization in the management of patients
isolates of spinal cord injury patients from the community and hospital. Spinal Cord 2014;52:298-301. with spinal cord injuries: Analysis of upper and lower urinary tract complications. BJU Int 2008;101:1396-
https://doi.org/10.1038/sc.2014.10 400. https://doi.org/10.1111/j.1464-410X.2007.07404.x
79. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) guidelines on 104. Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1987;1:823-54.
neuro-urology. Eur Urol 2016;69:324-33. https://doi.org/10.1016/j.eururo.2015.07.071 105. Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactiv-
80. Goetz LL, Cardenas DD, Kennelly M, et al. International spinal cord injury urinary tract infection basic data ity: A systematic review and meta-analysis. Eur Urol 2012;62:816-30. https://doi.org/10.1016/j.
set. Spinal Cord 2013;51:700-4. https://doi.org/10.1038/sc.2013.72 eururo.2012.02.036
81. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated 106. Madersbacher H, Murtz G, Stohrer M. Neurogenic detrusor overactivity in adults: A review on efficacy,
urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases tolerability, and safety of oral anti-muscarinics. Spinal Cord 2013;51:432-41. https://doi.org/10.1038/
Society of America. Clin Infect Dis 2010;50:625-63. https://doi.org/10.1086/650482 sc.2013.19
82. Krebs J, Wollner J, Pannek J. Risk factors for symptomatic urinary tract infections in individuals with chronic 107. Bennett N, O’Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic
neurogenic lower urinary tract dysfunction. Spinal Cord 2016;54:682-6. https://doi.org/10.1038/ bladder? J Urol 2004;171:749-51. https://doi.org/10.1097/01.ju.0000103274.38694.b1
sc.2015.214 108. Horstmann M, Schaefer T, Aguilar Y, et al. Neurogenic bladder treatment by doubling the recommended
83. Esclarin De Ruz A, Garcia Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract anti-muscarinic dosage. Neurourol Urodyn 2006;25:441-5. https://doi.org/10.1002/nau.20289
infection in patients with spinal cord injury. J Urol 2000;164:1285-9. https://doi.org/10.1016/ 109. Amend B, Hennenlotter J, Schäfer T, et al. Effective treatment of neurogenic detrusor dysfunction
S0022-5347(05)67157-1 by combined high-dosed anti-muscarinics without increased side-effects. Eur Urol 2008;53:1021-8.
84. Siddiq DM, Darouiche RO. New strategies to prevent catheter-associated urinary tract infections. Nat Rev https://doi.org/10.1016/j.eururo.2008.01.007
Urol 2012;9:305-14. https://doi.org/10.1038/nrurol.2012.68 110. Stöhrer M, Blok B, Castro-Diaz D, et al; European Association of Urology. Guidelines on neurogenic lower
85. Hartstein AI, Garber SB, Ward TT, et al. Nosocomial urinary tract infection: A prospective evaluation of 108 urinary tract dysfunction. Eur Urol 2009;56:81-8. https://doi.org/10.1016/j.eururo.2009.04.028
catheterized patients. Infect Control 1981;2:380-6. https://doi.org/10.1017/S0195941700055533 111. Çetinel B, Önal B, Can G, et al. Risk factors predicting upper urinary tract deterioration in patients with
86. Salameh A, Al Mohajer M, Daroucihe RO. Prevention of urinary tract infections in patients with spinal cord spinal cord injury: A retrospective study. Neurourol Urodyn 2017;36:653-8. https://doi.org/10.1002/
injury. CMAJ 2015;187:807-11. https://doi.org/10.1503/cmaj.141044 nau.22984
87. Cox L, He C, Bevins J, et al. Gentamicin bladder instillations decrease symptomatic urinary tract infec- 112. Kim YH, Bird ET, Priebe M, et al. The role of oxybutynin in spinal cord injured patients with indwelling
tions in neurogenic bladder patients on intermittent catheterization. Can Urol Assoc J 2017;11:E350-4. catheters. J Urol 1997;158:2083-6. https://doi.org/10.1016/S0022-5347(01)68161-8
https://doi.org/10.5489/cuaj.4434 113. Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a
88. Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary tract infection in persons new [beta]-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 2016;54:78-82.
with spinal cord dysfunction. Arch Phys Med Rehabil 2002;83:129-38. https://doi.org/10.1053/ https://doi.org/10.1038/sc.2015.195
apmr.2002.26605 114. Welk B. Urodynamic and clinical efficacy of mirabegron for neurogenic bladder patients. Ongoing study:
89. Krassioukov A, Warburton DE, Teasell R, et al; Spinal Cord Injury Rehabilitation Evidence Research Team. Clinical Trials. Gov Identifier NCT02044510.
A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med 115. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for
Rehabil 2009;90:682-95. https://doi.org/10.1016/j.apmr.2008.10.017 neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month
90. Walter M, Kran S, Nigro M, et al. OnabotulinumtoxinA for neurogenic detrusor overactivity not only study. J Urol 2005;174:196-200. https://doi.org/10.1097/01.ju.0000162035.73977.1c
reduces the frequency and severity of autonomic dysreflexia safely but significantly improves quality 116. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary
of life for individuals with spinal cord injury. Euro Urol 2018;17:e1357. https://doi.org/10.1016/ incontinence due to neurogenic detrusor overactivity: A randomized, double-blind, placebo-controlled trial.
S1569-9056(18)31782-2 Eur Urol 2011;60:742-50. https://doi.org/10.1016/j.eururo.2011.07.002
91. Zlatev DV, Shem K, Elliott CS. How many spinal cord injury patients can catheterize their own bladder? The 117. Mehta S, Hill D, McIntyre A, et al. Meta-analysis of botulinum toxin A detrusor injections in the treatment
epidemiology of upper extremity function as it affects bladder management. Spinal Cord 2016;54:287-91. of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil 2013;94:1473-81.
https://doi.org/10.1038/sc.2015.169 https://doi.org/10.1016/j.apmr.2013.04.011
92. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured 118. Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison
patients. J Urol 2000;163:768-72. https://doi.org/10.1016/S0022-5347(05)67800-7 of standardized mean outcomes for the use of botulinum toxin in the management of lower urinary tract
93. McIntyre A, Cheung KY, Kwok C, et al. Quality of life and bladder management post-spinal cord injury: A disorders. Eur Urol 2014;65:981-90. https://doi.org/10.1016/j.eururo.2013.10.033
systematic review. Appl Res Qual Life 2014;9:1081-96. https://doi.org/10.1007/s11482-013-9289-8 119. Cheng T, Shuang WB, Jia DD, et al. Efficacy and safety of onabotulinumtoxinA in patients with neurogenic
94. Jamil F. Towards a catheter-free status in neurogenic bladder dysfunction: A review of bladder manage- detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. PLoS One
ment options in spinal cord injury (SCI). Spinal Cord 2001;39:355-61. https://doi.org/10.1038/ 2016;11:e0159307. https://doi.org/10.1371/journal.pone.0159307
sj.sc.3101132 120. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 effi cacy and tolerability study of onabotulinum-Phase 3 efficacy and tolerability study of onabotulinum-
95. Gao Y, Danforth T, Ginsberg DA. Urologic management and complications in spinal cord injury patients: A 40- toxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-9.
to 50-year followup study. Urology 2017;104:52-8. https://doi.org/10.1016/j.urology.2017.03.006 https://doi.org/10.1016/j.juro.2012.01.125

CUAJ • June 2019 • Volume 13, Issue 6 E173